Created on Monday, 07 Nov 2016. Posted in Funding Tips
HTA the largest of the NIHR programmes and is the last stage in the translational pathway. The scheme funds definitive studies looking at effectiveness, costs and broader impact of healthcare treatments and tests.
There are no fixed limits on duration or funding but value for money must be demonstrated. The application process can take of 12 months and there is a 25% success rate for second stage submissions.
To be successful in getting funding you’ll need to convince the panel of the:
Quantify the health burden, how many people are eligible to use the new intervention (rare conditions research can be funded if there is a severe impact to health that would be improved by an intervention).
Quality of life is very important as many people have co-morbidities. Years gained and outcomes of ‘major events’ are all important measures (lives saved often inappropriate).
The panel isn’t interested in how much the disease costs, so much as how much could be saved by the intervention. It is hard to get data on impact measures such as changes to NIHR staffing, equipment, training etc but they’d all be relevant.
Impact on society can also be used here ie an intervention that could enable patients of working age to go back to work or increase productivity.
The research question must be important to clinicians. Ideal is if you can show variation in clinical decision making or show an uncertainty in clinical guidelines as this provides a powerful evidence of need.
If research recommendations aren’t available it is possible to generate them yourself by carrying out surveys and priority-setting exercises.
Value for Money
Cost per patient recruited good marker to see if the research is worth the cost (>£1,000 per patient). Trials costing more than £2-3 million need to be really important or show big impacts. However trials need to be deliverable for the money so if you cost too low your bid is also likely to fail.
When justifying the cost make is clear and explicit how it will work – flash statements won’t work, they need to be backed up with arguments.
If you get public involvement wrong you won’t get funded. So ensure you are measuring patient centred outcomes to give you the best chance to recruit patients and minimise drop out during the trial.
Make sure you have solid feedback and dissemination plans in place.